Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ticagrelor+ Aspirin · 1 trial · 2 indications
Non-ICH major hemorrhage is derived from the International Society on Thrombosis and Haemostasis (ISTH) criteria consisting of any of the following: * Fatal bleeding * Symptomatic bleeding in a critical area or organ, such as subarachnoid, intraventricular, subdural, epidural, spinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome * Symptomatic bleeding causing a fall in hemoglobin level of 1.24 mmol/L (20g/L or greater) or more, or leading to transfusion of two units or more of whole blood or red cells
The definition of ischemic stroke is the American Heart Association definition that includes acute focal signs or symptoms of cerebral, spinal cord, or retinal involvement of any duration associated with imaging, pathological, or other objective evidence of arterial infarction OR clinical evidence of cerebral, spinal cord, or retinal focal arterial ischemic injury based on symptoms persisting greater than or equal to 24 hours.
| Arm | Type | Description |
|---|---|---|
| Experimental Arm: Ticagrelor and Aspirin | EXPERIMENTAL | Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily) |
| Standard of Care Arm: Clopidogrel and Aspirin | ACTIVE_COMPARATOR | Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily) |
| Experimental Arm: Rivaroxaban and Aspirin | EXPERIMENTAL | Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily) |
| Name | Type | Description |
|---|---|---|
| Ticagrelor + Aspirin | DRUG | ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily) |
| Rivaroxaban + Aspirin | DRUG | low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily) |
| Clopidogrel + Aspirin | DRUG | clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily) |
| Risk Factor Management | OTHER | Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed. |
Inclusion Criteria: * Acute focal symptoms or signs of any duration associated with imaging, pathological, or other objective evidence of arterial infarction OR clinical evidence of cerebral, spinal cord, or retinal focal arterial ischemic injury based on symptoms persisting greater than or equal t...
Ticagrelor + Aspirin is an investigational combination of two small-molecule drugs being studied for the treatment of Intracranial Arteriosclerosis, a condition involving narrowing of arteries in the brain that can lead to stroke. It is currently in Phase 3 clinical development and has not been approved by the FDA.
Ticagrelor + Aspirin combines two antiplatelet agents that work by different mechanisms to reduce blood clot formation. Ticagrelor inhibits the P2Y12 receptor on platelets, while aspirin irreversibly inhibits the COX-1 enzyme, together decreasing platelet aggregation and the risk of thrombotic events in patients with Intracranial Arteriosclerosis.
Ticagrelor + Aspirin is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The combination is currently in Phase 3 clinical trials for Intracranial Arteriosclerosis.
Ticagrelor + Aspirin is in Phase 3 clinical development. It is an investigational combination therapy that has not yet received FDA approval. The ongoing Phase 3 trial is active but not recruiting participants, with a planned enrollment of 1,683 patients.
Ticagrelor + Aspirin is being evaluated in a Phase 3 trial with the identifier NCT05047172, titled 'Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis.' This randomized, double-blind, active-controlled study enrolls adults aged 30 and older in the United States and is currently active but not recruiting.
Yes, Ticagrelor + Aspirin is also known as Ticagrelor + Aspirin. This combination therapy is being studied under the same name in clinical trials for Intracranial Arteriosclerosis, and no alternative brand names have been reported.